Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Feature
Nature Biotechnology 26, 393–395 (1 April 2008) | doi:10.1038/nbt0408-393
Patenting pluripotence: the next battle for stem cell intellectual property
&
Abstract
The last 12 months have been a watershed for major developments in stem cell intellectual property (IP). After reexamination proceedings held in March 2007, the US Patent and Trademark Office (USPTO; Washington, DC) issued a preliminary rejection of three of James Thomson's foundational embryonic stem (ES) cell patents (commonly known as '780, '806 and '913; Table 1).
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
